DNA-Repair ERCC1 Gene Polymorphisms in Epithelial Ovarian Cancer and Relation to Platinum Resistance and Survival by Dahl Steffensen, Karina et al.
Journal of Cancer Therapy, 2011, 2, 140-147 
doi:10.4236/jct.2011.22016 Published Online June 2011 (http://www.SciRP.org/journal/jct) 
Copyright © 2011 SciRes.                                                                                  JCT 
DNA-Repair ERCC1 Gene Polymorphisms in 
Epithelial Ovarian Cancer and Relation to 
Platinum Resistance and Survival 
Karina Dahl Steffensen1,2, Marianne Waldstrøm3, Anders Jakobsen1,2 
 
1Department of Oncology, Vejle Hospital, Vejle, Denmark; 2Institute of Regional Health Services Research, University of Southern 
Denmark, Odense C, Denmark; 3Pathology, Vejle Hospital, Vejle, Denmark. 
Email: Karina.Dahl.Steffensen@slb.regionsyddanmark.dk 
 
Received March 3rd, 2011; revised April 20th, 2011; accepted April 30th, 2011. 
 
ABSTRACT 
Objectives: Excision repair cross-complementation group 1 (ERCC1) is a key DNA repair gene in the nucleotide exci-
sion repair pathway which is activated in the repair of intra- and interstrand DNA crosslink caused by platinum-based 
treatment. Two single nucleotide polymorphisms (SNPs) of the ERCC1 gene, codon 118 C/T and C8092A, have been 
reported to be functional, but the influence on platinum resistance and survival is not yet clear. The primary aim of the 
present study was to investigate whether the two SNPs were associated with resistance to standard combination car-
boplatin and paclitaxel chemotherapy and the potential prognostic impact in newly diagnosed ovarian cancer patients. 
Methods: Serum samples from 202 patients with newly diagnosed ovarian cancer were assessed for ERCC1 SNP geno-
typing using real time PCR. All patients were treated with first line carboplatin/paclitaxel chemotherapy. Results: 
There were no correlation between the ERCC1 118 C/T and C8092A genotypes and platinum resistance (P = 0.79 and 
P = 0.36, respectively). Furthermore, the results showed no association to progression free survival (P = 0.18 and P = 
0.16, respectively) or overall survival (P = 0.89 and P = 0.78, respectively) for the two SNPs. Conclusions: The 
ERCC1 118 C/T and C8092A polymorphisms did not have significant influence on clinical outcome defined as platinum 
resistance, PFS and OS. 
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1. Introduction 
Differences in chemotherapy response and patient sur-
vival may be related to inter individual genetic polymor-
phisms in patient’s genes since they can change the ex-
pression or the function of enzymes related to the me-
tabolism of the chemotherapeutic drug offered to the 
patient. 
Ovarian cancer is considered a chemo sensitive tumor 
as 70% - 85% of patients with advanced ovarian cancer 
respond to standard combination taxane/platinum-based 
treatment following primary surgical debulking [1]. De-
spite this apparent efficacy of treatment, the majority of 
these patients will relapse within a few years and if not 
already present, ultimately chemotherapy resistance will 
occur. Especially, the development of tumor resistance to 
platinum compounds is a major clinical problem in the 
treatment of ovarian cancer. Although the molecular 
mechanisms of platinum resistance are complex and mul- 
tifactorial, DNA repair is essential to clinical drug resis-
tance [2-4]. 
Excision repair cross-complementation group 1 (ERCC1) 
is a key DNA repair gene in the nucleotide excision repair 
pathway (NER) [5-7]. This important pathway is acti-
vated in the repair of intra- and inter-strand DNA 
crosslink caused by platinum-based treatment. Excision 
of the formed DNA adducts is carried out by nucleotide 
excision repair proteins [8] that recognize the DNA dam-
age and excise the cytotoxic platinum-DNA adducts from 
the injured DNA strand.  
ERCC1 gene and protein expression have been found 
to be inversely correlated with response to platinum- 
based chemotherapy in ovarian cancer patients [9-11]. 
Furthermore, preclinical studies have also suggested 
that the expression levels of ERCC1 mRNA are related to 
platinum resistance. In ovarian cancer cell lines a 3-fold 
higher expression of ERCC1 mRNA was correlated with 
cisplatin resistance [12]. 
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Single nucleotide polymorphisms (SNPs) in the ERCC1 
gene may affect the function of the encoding gene. The 
ERCC1 gene, on chromosome 19q13.2 - q13.3, encodes a 
protein of 297 amino acids. Two common polymorphisms 
of the ERCC1 gene, 118 C/T (rs11615) and C8092A 
(rs3212986), have been reported [13-15]. The single nu-
cleotide polymorphism (SNP) at codon 118 (position 
19007/also synonymous with T19007C) causes a C > T 
change that codes for the same amino acid, asparagine, 
and it has been proposed to impair ERCC1 translation 
and reduce ERCC1 protein expression in cells, and 
thereby, effect the response to platinum based chemo-
therapy [15-17]. The C8092A polymorphism, located in 
position 8092 of the 3’-untranslated region of the gene 
consisting of a C > A change, may be involved in transla-
tional repression of ERCC1 mRNA [18] or affect ERCC1 
mRNA stability resulting in impaired DNA repair capac-
ity and has also been associated with the risk of adult- 
onset glioma [19].  
The primary aim of the present study was to investi-
gate whether the two gene polymorphisms, ERCC1 118 
C/T and C8092A were associated with resistance to stan-
dard combination carboplatin and paclitaxel chemother-
apy and furthermore, to evaluate the potential prognostic 
impact in newly diagnosed ovarian cancer patients. 
2. Materials and Methods 
2.1. Ethics Statement 
Patients received both oral and written information at the 
respective departments of clinical oncology before they 
signed an informed consent prior to collection of bio-
logical material. The study was conducted according to 
the principles expressed in the Declaration of Helsinki. 
The Danish Biomedical Research Ethics Committee and 
the Danish Data Protection Agency approved the study. 
2.2. Study Population 
Two hundred and two newly diagnosed ovarian cancer 
patients, stage I-IV, were included from four different 
Danish hospitals. The patients had histological confirmed 
epithelial ovarian cancer and all tumor specimens un-
derwent central pathology revision. 
The majority of the patients underwent primary de-
bulking surgery while minor parts (N = 38, 18.8 %) were 
treated with neoadjuvant chemotherapy. They all re-
ceived first line combination chemotherapy with car-
boplatin (AUC5) and paclitaxel (175 mg/m²). Treatment 
was administered every 3 weeks for at least four cycles. 
Platinum sensitivity was defined as time to recurrence 
> 6 months after completion of first line platinum-based 
chemotherapy and platinum-resistance as recurrence ≤ 6 
months after completion of first line platinum-based 
chemotherapy or progression during the first line plati-
num-based chemotherapy. 
Recurrence of disease was evaluated as according to 
the Gynecologic Cancer Inter Group (GCIG) CA125 
criteria’s [20,21] defined as an elevation of CA125 of at 
least twice the nadir value (and above upper normal level) 
or to twice the upper normal level (in patients that 
achieved normalization of CA125 during first line treat-
ment) and radiological confirmation of tumor. 
As a part of this translational research protocol the pa-
tients provided peripheral blood samples for translational 
research at baseline and at each chemotherapy treatment 
cycle (day 1). 
2.3. ERCC1 Genotyping 
DNA was extracted and purified from white blood cells 
recovered from the whole blood samples using the Max-
well® 16 Blood DNA Purification Kit (Cat. # AS1010, 
Maxwell Promega, Madison, WI 53711, USA). 
The ERCC1 codon 118 C/T and C8092A polymor-
phisms were detected by polymerase chain reactions (PCR) 
using the 7900HT real-time PCR system (Applied Biosys-
tems, CA 94404, USA. www.appliedbiosystems.com).  
PCR reactions were set up in 10 μl reaction volume 
including 2 μl DNA and 8 μl TaqMan® Universal PCR 
Master Mix. TaqMan® validated SNP genotyping assay 
c__2532959_1_ for the ERCC1 codon 118 polymorphism 
(rs11615) and assay c__2532948_10 for the C8092A 
(rs3212986) polymorphisms were used. 
After PCR amplification an endpoint plate read was 
performed and the final products were analyzed by the 
SDS (Sequence Detection Systems) software. 
For quality controls known genomic DNA controls 
were included together with NTC (No Template Con-
trol). 
2.4. Statistical Analysis 
All clinical data and follow data were prospectively col-
lected as part of a translational study protocol and the 
data were entered into case report forms. The correlation 
between ERCC1 polymorphisms and clinicopathological 
parameters was assessed by chi-square statistics and the 
same applied to the association between ERCC1 poly-
morphisms and response/resistance to chemotherapy. 
The haplotypes were estimated using the Bayesian al-
gorithm in the PHASE program version 2.1.1 [22,23], 
which is available at http://stephenslab.uchicago.edu/soft 
ware.html. 
Progression free survival (PFS) was defined as the 
time from date of diagnosis (date of primary surgery/ 
biopsy) until disease recurrence or death, whichever 
came first. Overall survival (OS) was defined as the time 
from date of diagnosis until death regardless of cause. 
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Univariate overall survival analysis was performed using 
the Kaplan-Meier method and log-rank statistics for 
comparison of survival curves. Multivariate progres-
sion-free and overall survival analysis was performed by 
the Cox regression model. The parameters entered in the 
Cox analysis were FIGO stage, grade, residual disease 
status, histology, age groups and the two SNPs as cate-
gorical variables. For the multivariate analysis, histology 
was divided into serous and non-serous, FIGO stages 
were divided into stage I/II vs. III/IV and grade into 
grade 1 vs. grade 2/3/not graded due to too many pa-
rameters (according to the number of events) in multi-
variate analyses if not merged into fewer groups. 
Statistical significance was defined as a probability 
level, p < 0.05. 
Statistical analyses were performed with the Number 
Cruncher Statistical System (NCSS) software (version 
2007, Kaysville, Utah, www.ncss.com).  
3. Results 
3.1. Patients and Allele Frequencies 
Genotyping for the two ERCC1 polymorphisms were 
obtained for all 202 patients. 
The frequencies of the different gene polymorphism 
are shown in Table 1 along with the patient’s character-
istics. Concerning ERCC1 C8092A only ten patients (5%) 
harbored the more uncommon AA polymorphic homo-
zygotic genotype. According to the NCBI database, the 
C8092A genotype is found in approximately 5% in the 
European population. This is in consistence with our 
findings. 
The observed number of each genotype was compared 
with that expected for a population in Hardy-Weinberg 
equilibrium and the investigated population showed no 
differences from this distribution (p = 0.99 for ERCC1 
118 C/T and p = 0.90 for ERCC1 C8092A, χ²). 
Linkage disequilibrium between the two polymorphic 
loci was observed (D = –0.148 and r2 = 0.54). The patient 
cohort was mainly composed of advanced stage patients 
with high grade serous tumors which are the most com-
mon presentation of epithelial ovarian cancer at diagno-
sis. 
Six cycles of chemotherapy treatment were adminis-
tered to 85% of the patients and 98% received at least 
three cycles. Thirteen patients received more than six 
cycles due to an expectation of a further tumor response 
with prolonged treatment up to a maximum of nine cy-
cles. 
One patient received only one cycle. This patient died 
two days after the first cycle of carboplatin and paclitaxel. 
The subsequent autopsy revealed that the patient died due 
to a lobar pneumonia and acute hemorrhagic gastritis.  
Table 1. Patient characteristics. 
Characteristics No. of patients % 
Age 
   <50 
   51 - 65 
   >65 
             Median       65 
             Range       32 - 89 
 
 
17 
87 
98 
 
 
 
8.4 
43.1 
48.5 
 
 
FIGO stage 
   I 
   II 
   III 
   IV 
 
 
28 
15 
111 
48 
 
 
13.9 
7.4 
55.0 
23.8 
 
Tumor grade 
   1 
   2 
   3 
   Not graded (clear cell or metastatic 
   biopsy/cytology only)  
 
 
20 
66 
81 
35 
 
9.9 
32.7 
40.1 
17.3 
Histopathologic cell type 
   Serous 
   Endometrioid 
   Clear cell 
   Mucinous  
   Carcinomas (cytology only, mixed 
or undifferentiated) 
   
165 
14 
11 
4 
8 
 
81.7 
6.9 
5.5 
2.0 
4.0 
 
Residual postoperative tumor 
   ≤1 cm 
   >1 cm 
   (Unknown: 9)  
 
 
97 
96 
 
 
50.3 
49.7 
ERCC1 118 C/T   
   CC 
   CT 
   TT 
 
 
24 
91 
87 
 
 
11.9 
45.1 
43.1 
 
ERCC1 C8092A  
   CC 
   CA 
   AA 
 
116 
76 
10 
 
57.4 
37.6 
5.0 
 
There were no correlation between SNPs and any of the 
classical clinicopathological variables (data not shown). 
3.2. Association between ERCC1 SNPs and  
Platinum Resistance 
The clinical response to the combination platinum- pacli-
taxel chemotherapy was assessed for all patients by the 
end of every third cycle. CA125 was measured at each 
cycle. The majority of the patients (157/202, (78%)) had 
measurable disease at baseline, prior to the first cycle of 
combination chemotherapy by modified GCIG CA125 
criteria’s [20,21] and/or by Response Evaluation Criteria 
In Solid Tumors (RECIST) criteria’s.  
After completion of the first line chemotherapy 59% 
of the patients with measurable disease had complete 
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response and 32% had partial response. Only 13 patients 
(8%) did not respond to the first line treatment. 
It appears from Table 2(a) that there were no correla-
tion between the SNP genotypes and response to chemo-
ther apy. However, it should be noticed that only a very 
limited number of patients (N = 13) progressed or had 
stable disease during first line treatment making any sta-
tistical correlation between response rates and ERCC1 
SNPs dubious.  
At the time of analysis, recurrence data at 6 months 
follow up were available for 155 patients and 56 patients 
has progressed within 6 months of completion of che-
motherapy. 
As shown in Table 2(b) the SNP genotypes did not 
significantly correlate with platinum resistance defined 
as recurrence within 6 months of completed therapy. 
3.3. Association between ERCC1 SNPs and  
Survival 
Progression free and overall survival curves were esti-
mated by the Kaplan-Meier method and the Kaplan- 
Meier survival curves are shown in Figure 1. 
The Kaplan-Meier survival plots showed no statisti-
cally significant relationship between SNP genotypes and 
progression-free or overall survival. 
For ERCC 118 C/T the Kaplan Meier estimate of me-
dian PFS for patients with ERCC1 118 C/C, C/T and T/T 
were 11.3, 19.3 and 13.9 months, respectively while the 
median PFS of patients with ERCC1 C8092A C/C, C/A 
and A/A were 14.1, 19.6 and 9.5 months respectively. 
Patients with the ERCC1 118 CC and the ERCC1 8092 
AA genotype graphically appeared to have a poor pro-
gression free survival, but these group were rather small 
(N = 24 and N = 10) and there were no statistically sig-
nificant differences. 
The Kaplan Meier estimate of median OS for patients 
with ERCC1 118 C/T, were 37.5 months for C/C, 39.6 
months for C/T and 42.9 months for the T/T genotype, (p 
= 0.89). The median OS of patients with ERCC1 C8092A 
C/C, C/A and A/A were 42.9, 40.7 and 35.7 months, re-
spectively (p = 0.78). 
Furthermore, multivariate analysis showed no inde-
pendent influence of the two SNPs on PFS or OS (Table 
3).  
3.4. Haplotype Analysis 
Haplotype analysis was conducted to evaluate the com-
bined effect of the two polymorphisms of the ERCC1 
gene, 118 C/T and C8092A on platinum resistance, PFS 
and OS. The four possible haplotypes in this cohort of 
ovarian cancer patients were CC (11.4%), CA (22.9%), 
TC (64.8%), and TA (0.9%).  
No significant associations were found between hap-
lotypes and platinum-resistance, e.g. 35% patients carry-
ing the TC haplotype were platinum-resistant compared 
to 47 % among patients not carrying the TC haplotype, p 
= 0.42, Fisher’s exact test (data not shown). 
For patients carrying at least one allele with the TC 
haplotype (87.6% of the patients) an increased progres-
sion-free survival (p = 0.04) was found compared with 
patients not harboring the TC haplotype (data not shown). 
This increased PFS did not translate into a better overall 
survival for patients with the TC haplotype (p = 0.9, data 
not shown).  
Multivariate analysis did not showed improved PFS 
(HR 0.57 [0.31-1.03, 95% CI], p = 0.06) or OS (HR 0.75 
[0.37 - 1.51, 95% CI], p = 0.42) for the TC haplotype 
(data not shown). 
 
Table 2 (a). Correlation between and ERCC1 SNPs and response (N = 157 patients with measurable disease). 
 ERCC1 118 C/T p ERCC1 C8092A p 
 CC (n = 17) CT (n = 75) TT (n = 65)  CC (n = 89) CA (n = 61) AA (n = 7)  
Response    0.44    0.53
CR + PR* (n = 144) 15 (88%) 71 (95%) 58 (89%)  80 (90%) 57 (93%) 7 (100%)  
SD + PD* (n = 13) 2 (12%) 4 (5%) 7 (11%)  9 (10%) 4 (7%) 0 (0%)  
*CR: Complete response, PR: Partial response, SD: Stable disease, PD: Progressive disease. P values refer to the p-value from Fisher’s exact test by cross tabu-
lation. 
 
Table 2 (b). Correlation between and ERCC1 SNPs and platinum resistance (N = 155 with follow up > 6 months). 
 ERCC1 118 C/T p ERCC1 C8092A p 
 CC (n = 16) CT (n = 72) TT (n = 67)  CC (n = 89) CA (n = 61) AA (n = 7)  
Resistance    0.79    0.36
Relapse > 6 months (n = 99) 9 (56%) 47 (65%) 43 (64%)  62 (67%) 35 (60%) 2 (40%)  
Relapse < 6 months (n = 56) 7 (44%) 25 (35%) 24 (36%)  30 (33%) 23 (40%) 3 (60%)  
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Figure 1. Kaplan-Meier estimates of PFS and OS for patients with the ERCC1 118 C/T and ERCC1 C8092A genotypes. 
 
Table 3. Multivariate analysis (COX). 
PFS (105 events) OS (66 events)  Clinicopathological 
Characteristics* HR 95% CI** p HR 95% CI** p 
Age 
  <50 
  50 - 65 
  >65 
 
1.00 
0.73 
0.65 
 
 
0.28 - 1.91 
0.25 - 1.72 
 
 
0.518 
0.389 
 
1.00 
1.14 
1.27 
 
 
0.31 - 4.19 
0.34 - 4.75 
 
 
0.840 
0.719 
FIGO stage 
  I/II 
  III/IV 
 
1.00 
4.95 
 
 
1.97 - 12.4 
 
 
<10–3 
 
1.00 
5.62 
 
 
1.23 - 25.7 
 
 
0.026 
Tumor grade 
  1 
  2/3/not graded 
 
1.00 
3.74 
 
 
0.86 - 16.3 
 
 
0.079 
 
1.00 
1.06 
 
 
0.23 - 4.93 
 
 
0.936 
Histology 
  Serous 
  Non-Serous 
 
1.00 
1.32 
 
 
0.66 - 2.65 
 
 
0.438 
 
1.00 
1.41 
 
 
0.63 - 3.15 
 
 
0.406 
Residual tumor 
     0 cm   
 ≤1 cm 
>1 cm 
 
1.00 
3.27 
3.13 
 
 
1.63 - 6.59 
1.70 - 5.74 
 
 
<10–3 
<10–3 
 
1.00 
2.29 
3.85 
 
 
0.83 - 6.33 
1.57 - 9.43 
 
 
0.111 
0.003 
ERCC1 118 C/T   
   CC 
   CT 
   TT 
 
1.00 
0.52 
0.60 
 
 
0.25 - 1.10 
0.25 - 1.48 
 
 
0.086 
0.271 
 
1.00 
0.90 
0.87 
 
 
0.37 - 2.17 
0.26 - 2.89 
 
 
0.808 
0.826 
ERCC1 C8092A  
   CC 
   CA 
   AA 
 
1.00 
1.12 
0.85 
 
 
0.60 - 2.07 
0.20 - 3.67 
 
 
0.722 
0.825 
 
1.00 
1.22 
1.43 
 
 
0.50 - 2.97 
0.26 - 7.81 
 
 
0.661 
0.677 
*Only patients where the status was known for all potential prognostic parameters: Age, FIGO stage, tumor grade, histology, residual disease status and SNP 
status were included for PFS (N = 183 patients) and OS (N = 183 patients) analysis. **Adjusted 95% CI with adjustment for age, FIGO stage, tumor grade, 
histology, residual disease status and genetic factors. 
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4. Discussion 
Inter individual variation in chemotherapy response is a 
major factor in ovarian cancer.  
Identifying parameters with influence on this variabil-
ity may allow individualized and more effective treat-
ments offered to patients. Single nucleotide polymor-
phisms may contribute to inter individual variability in 
DNA repair capacity and therefore predict outcome for 
platinum based chemotherapy. Polymorphisms in the 
ERCC1 gene have been implicated in response to plati-
num-based chemotherapy in several tumor types [13,24, 
25], but data on ovarian cancer are still limited and con-
tradictory. 
The role of the two ERCC1 polymorphisms in the sur-
vival of ovarian cancer patients have been evaluated in a 
few other ovarian cancer studies with conflicting results. 
ERCC1 118 C/T polymorphism was investigated in a 
study by Smith et al. [26] who showed that the C/C 
genotype was associated with an impaired PFS (HR = 
1.95, p = 0.051) and OS (HR = 2.01, p = 0.033). How-
ever, this was only shown in the subgroup of patients 
treated with platinum without paclitaxel, but not in the 
group treated with combination paclitaxel/platinum sug-
gesting that the influence of the ERCC1 118 C/C geno-
type was minimized by the addition of a taxane which 
targets microtubules rather than DNA.  
In the presented study the ERCC1 118 C/T polymor-
phism did not seem to be associated with clinical out-
come, since we were not able to detect a significant cor-
relation to platinum resistance or to PFS/OS. In agree-
ment with the current study, three other studies in ovar-
ian cancer were similarly not able to detect any influence 
of the ERCC1 118 C/T polymorphism on PFS or OS 
[27-29]. 
Another study by Kang et al. [30] demonstrated that 
platinum resistance was less frequently observed in pa-
tients with the C/T and T/T genotype (p = 0.018) and the 
same findings has been presented in a previous work by 
our group [10] investigating ERCC 118 C/T polymor-
phism in another ovarian cancer cohort showing that the 
T/T genotype had significantly better CA125 response (P 
= 0.045) in first line treatment although neither of these 
two studies showed any correlation to OS. The same ap-
plied to the present study in which no correlation with 
SNPs and OS was found. Interestingly, the former study 
by our group was performed on ovarian cancer patients 
treated with carboplatin and cyclophosphamide and sup-
ports to some extend the work by Smith et al. [26] de-
scribed previously in which the ERCC1 118 polymor-
phism only seemed to have clinical impact in patients not 
treated with a taxane.  
With respect to the C8092A polymorphism, we did not 
find any influence of C8092A polymorphism to clinical 
outcome. In agreement with the results presented, a very 
large trial [27] including 914 ovarian cancer patients did 
not either show any correlation of C8092A polymor-
phism to PFS or OS.  
Nevertheless, this is in contrast with two other studies 
on ovarian cancer that both showed significantly longer 
PFS and OS in patients with the C/C genotype. One 
study [29] with 233 patients showed 68.6 months median 
survival in patients with the C/C genotype compared to 
51.6 months for patients with the C/A + A/A genotypes 
(p = 0.047, p = 0.018 in multivariate analysis). The sec-
ond study [28] did not show any correlation with re-
sponse but reported a HR of 1.94 (p = 0.03) for the C/A 
+ A/A for worse OS compared to the C/C genotype. The 
conflicting results also apply to other tumor types. Two 
studies in non-small cell lung cancer patients also re-
ported worse survival for the A/C + A/A genotypes [24, 
25]. A third non-small cell lung cancer study [31] has in 
discrepancy with these results shown significantly asso-
ciation of the 8092 A allele with longer OS in univariate 
and multivariate analysis. 
Noteworthy, our study supports several other studies 
[24,29,31] suggesting that the ERCC1 118 C/T and 
C8092A SNPs may be in linkage disequilibrium. 
The selection of one single locus as having sufficient 
phenotypic effect to impact on clinical outcome may be 
an oversimplification. There are many different pathways 
involved in DNA repair and even within the NER path-
way several proteins are involved in the repair process 
although the ERCC1 protein is one of the key enzymes in 
this pathway. 
The SNPs may not have any impact of the protein 
level. In the present study (data not presented, the 
ERCC1 protein data has been previously presented else-
where [11]), as well as in another recently published 
study in non-small cell lung cancer [25], no correlation 
between ERCC1 SNP genotypes and ERCC1 protein 
expression were found. Beside changes in the encoding 
protein sequence, multiple other mechanisms such as 
gene regulation (e.g. polymorphisms in the promoter 
region or promoter methylation), mRNA processing (e.g. 
splicing, mRNA modification and turnover) and transla-
tion (e.g. microRNA induced inhibition of translation) 
can cause phenotypic changes.  
5. Conclusions 
The ERCC1 118 C/T and C8092A polymorphisms were 
not found to have significant influence on clinical out-
come defined as platinum resistance, PFS and OS and 
were therefore not effective tools in selecting patients 
most likely to benefit to platinum-based chemotherapy.  
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